It pays to take history into account as well in cases like these. I remember the incredible hype surrounding the obesity pill market in the USA in 2011 & 2012. Arena Pharmaceuticals shot up after FDA approval with Belviq, then promptly tanked and has NEVER recovered as sales have since then been much less than expected. Vivus was next with Qysimia, which again shot up on FDA approval... then tanked... and never recovered. These companies are still yet to be profitable, even with a massive potential market, being US based and despite HUGE marketting schemes for their products.
Point is, the hype and excitement phase was great, but it never lasts. PEB needs to start delivering, and delivering WELL ABOVE ITS WEIGHT. If it cannot, this company will be another VVUS or ARNA, no matter what MAC says and not matter how many DCF models he makes.
ARNA chart:
https://nz.finance.yahoo.com/q/bc?s=...=on&z=l&q=l&c=
VVUS chart:
https://nz.finance.yahoo.com/q/bc?s=VVUS&t=5y
Read carefully:
IT IS NOT DIFFERENT THIS TIME!!!!